MedTrace Logo

Protective Effect in Cardiac Surgery Patients

NCT04028024 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2019-07-22

No results posted yet for this study

Summary

The purpose of the study was to verify the protective effect of inhibiting systemic inflammatory response in patients undergoing cardiac surgery.

Conditions

  • Cardiac Surgery

Interventions

DRUG

Ulinastatin

Ulinastatin 5000U/Kg in 20 ml NS i.v. before occlusion of aorta

Sponsors & Collaborators

  • Shanghai Zhongshan Hospital

    lead OTHER

Principal Investigators

  • Hui-lin Wang, Phd · Fudan University

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-08-01
Primary Completion
2020-12-31
Completion
2021-06-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04028024 on ClinicalTrials.gov